COR
NYSECENCORA, INC.
Consumer Defensive · Wholesale-Drugs, Proprietaries & Druggists' Sundries
Research view
Fundamentals · SEC EDGAR · FY 2025-09-30
Revenue & Earnings — fiscal year
$214.0B
2021
$238.6B
2022
$262.2B
2023
$294.0B
2024
$321.3B
2025
Snapshot
SEC EDGAR · FY 2025-09-30Revenue$321.3B
Net Income$1.6B
Gross Profit$11.5B
Oper Income$2.6B
EPS (dil)$7.96
Rev/sh$1651.58
FCF/sh$16.48
Book/sh$8.98
Gross M3.6%
Oper M0.8%
Profit M0.5%
FCF M1.0%
ROE89.7%
ROA2.0%
ROIC35.6%
R&D/Rev—
Rev Y/Y9.3%
Rev 3Y CAGR10.4%
EPS Y/Y5.7%
EPS 3Y CAGR-0.3%
FCF 3Y CAGR13.3%
Payout28%
Div/sh$2.20
Shs Chg Y/Y-2.5%
Current Ratio0.90
Quick Ratio0.55
Debt/Eq4.45
Int Coverage—
Net Debt$3.4B
Total Debt$7.8B
Cash & Eq$4.4B
Total Assets$76.6B
Oper CF$3.9B
Capex$668.0M
Free CF$3.2B
Buybacks$435.5M
Equity$1.7B
Liabilities—
Shs Outstand0.19B
SectorConsumer Defensive
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $214.0B | $238.6B | $262.2B | $294.0B | $321.3B |
| Gross Profit | $6.9B | $8.3B | $9.0B | $9.9B | $11.5B |
| Operating Income | $2.4B | $2.4B | $2.3B | $2.2B | $2.6B |
| Net Income | $1.5B | $1.7B | $1.7B | $1.5B | $1.6B |
| Diluted EPS | $7.39 | $8.04 | $8.53 | $7.53 | $7.96 |
| Operating Cash Flow | $2.7B | $2.7B | $3.9B | $3.5B | $3.9B |
| Free Cash Flow | $2.2B | $2.2B | $3.5B | $3.0B | $3.2B |
COMMUNITY · $COR0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.